☆ 4.7 Article

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement

JOURNAL OF CLINICAL ONCOLOGY (2018)

Get Full Text
Add to Collection

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 6, Pages 617-+

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2017.75.8193

Keywords

-

Categories

Oncology

Funding

  1. Eli Lilly
  2. Bristol-Myers Squibb
  3. Dompe Farmaceutici
  4. Novartis
  5. Millennium
  6. Agensys
  7. Immunogen
  8. TetraLogic Pharmaceuticals
  9. Altor BioScience
  10. Incyte
  11. Onyx Pharmaceuticals
  12. MedImmune
  13. Genentech
  14. Regeneron Pharmaceuticals
  15. Atterocor
  16. Bayer AG
  17. Boston Biomedical
  18. Celgene
  19. Exelixis
  20. ImClone Systems
  21. Millennium Pharmaceuticals
  22. Oncogenex Pharmaceuticals
  23. OncoMed Pharmaceuticals
  24. Seattle Genetics
  25. Teva Pharmaceutical Industries
  26. Arbutus Biopharma
  27. Bristol-Myers Squibb/Medarex
  28. ESSA Pharma
  29. Medivation/Astellas
  30. Takeda
  31. AstraZeneca
  32. Bayer
  33. Merck
  34. Pfizer
  35. Janssen Research Development
  36. Puma Biotechnology
  37. Merrimack Pharmaceuticals
  38. Parexel
  39. Acerta Pharma
  40. Kite Pharma
  41. Allos Therapeutics
  42. Merck Sharp Dohme

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.